Krystal Biotech, Inc. (NASDAQ: KRYS) earned an average “Buy” recommendation from the seven rating companies that currently cover the stock, reports MarketBeat. One research analyst rated the stock with a keep recommendation and six issued a buy recommendation on the company. The average one-year target price among brokers who reported on the stock in the past year is $ 97.50.
A number of equity research analysts have weighed on the company recently. Goldman Sachs Group Downgraded Krystal Biotech from “Neutral” to “Buy” Rating and Raised Target Share Price from $ 73.00 to $ 90.00 in Published Research Report Tuesday July 20. William Blair reaffirmed a “buy” note on Krystal Biotech shares in a research report on Friday, July 2. Jonestrading reaffirmed a “buy” rating and set a price target of $ 97.00 on Krystal Biotech shares in a research report released on Friday, July 2. Chardan Capital reaffirmed a “buy” note on Krystal Biotech shares in a research note on Thursday July 1. Finally, Zacks Investment Research upgraded Krystal Biotech from a “sell” rating to a “conservation” rating in a Tuesday July 13th research note.
Institutional investors recently changed their positions in the stock. Redmile Group LLC increased its stake in Krystal Biotech shares by 23.0% during the first quarter. Redmile Group LLC now owns 2,060,132 shares of the company valued at $ 158,713,000 after purchasing an additional 385,096 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Krystal Biotech in the first quarter valued at approximately $ 287,000. The Swiss National Bank increased its stake in Krystal Biotech by 1.4% in the first quarter. The Swiss National Bank now owns 29,300 shares of the company valued at $ 2,257,000 after acquiring an additional 400 shares during the period. Northern Trust Corp increased its stake in Krystal Biotech by 3.2% in the first quarter. Northern Trust Corp now owns 178,642 shares of the company valued at $ 13,762,000 after acquiring an additional 5,516 shares during the period. Finally, the State Board of Administration of Florida Retirement System increased its stake in Krystal Biotech by 127.4% in the second quarter. The Florida State Pension System Board now owns 8,777 shares of the company valued at $ 597,000 after acquiring an additional 4,917 shares during the period. 73.80% of the shares are held by institutional investors and hedge funds.
KRYS shares opened at $ 51.60 on Friday. The company has a market cap of $ 1.15 billion, a price-to-earnings ratio of -20.64 and a beta of 1.15. Krystal Biotech has a 52 week low of $ 40.04 and a 52 week high of $ 87.29. The stock has a fifty-day moving average price of $ 56.59 and a two-hundred-day moving average price of $ 64.36.
Krystal Biotech (NASDAQ: KRYS) last released its results on Sunday, August 8. The company reported ($ 0.74) earnings per share for the quarter, beating analyst consensus estimates ($ 0.76) by $ 0.02. On average, sell-side analysts expect Krystal Biotech to post EPS of -2.96 for the current fiscal year.
Krystal Biotech Company Profile
Krystal Biotech, Inc is a gene therapy company dedicated to the development and commercialization of treatments for patients with dermatological conditions. He has developed a gene therapy platform, which the company calls the Skin TARgeted Delivery Platform, or STAR-D Platform, which consists of a patent-pending modified viral vector based on the herpes virus. simplex 1, or HSV-1, and a gene optimized for the skin. technology transfer, to develop off-the-shelf treatments for dermatological diseases.
Read more: What is a cross of death?
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Krystal Biotech now?
Before you consider Krystal Biotech, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Krystal Biotech was not on the list.
While Krystal Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here